Roche’s Actemra Gets Advisory Committee Review
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Arthritis Drugs Advisory Committee evaluates the interleukin-6 receptor inhibitor for rheumatoid arthritis July 29.
You may also be interested in...
Roche’s Actemra Gets FDA Panel Vote Of Confidence With Robust P-vigilance
Arthritis Drugs Advisory Committee selects more cautious starting dose for Roche’s rheumatoid arthritis therapy during July 29 meeting.
Roche’s Actemra Gets FDA Panel Vote Of Confidence With Robust P-vigilance
Arthritis Drugs Advisory Committee selects more cautious starting dose for Roche’s rheumatoid arthritis therapy during July 29 meeting.
FDA Calls Roche’s Arthritis Drug Actemra Effective Ahead Of Panel Meeting
First-in-class interleukin-6 receptor inhibitor may sidestep safety concerns seen with anti-TNFs.